Recombinant Human Brain and acute leukemia cytoplasmic protein (BAALC)

1. despite of their well-known adverse role in prognosis of AML, neither BAALC nor ERG expression levels at diagnosis had effect on survival of AML patients who underwent allo-HSCT. PMID: 29696374
2. BAALC expression-based minimal residual disease detection during therapy may be considered a strategy to identify patients at high risk of relapse. PMID: 27662611
3. Study provide evidence for an association of rs62527607 [GT] SNP of BAALC gene with multidrug resistance in childhood ALL. PMID: 27372260
4. BAALC and ERG genes are specific significant molecular markers in acute myeloid leukemia disease progression, response to treatment and survival. PMID: 26625814
5. demonstrated that BAALC blocks ERK-mediated monocytic differentiation of acute myeloid leukemia cells by trapping Kruppel-like factor 4 (KLF4) in the cytoplasm and inhibiting its function in the nucleus PMID: 26050649
6. combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers PMID: 26430723
7. study indicates that overexpression of BAALC serves as an independent prognostic biomarker in acute myeloid leukemia PMID: 25428390
8. Evaluating WT1 and BAALC gene expression at diagnosis may improve standard risk stratification and possibly refine the therapeutic approach for Myelodysplastic Syndromes patients. PMID: 26012361
9. Thus low MDR1/low BAALC expression identifies a subgroup of intermediate cytogenetic risk AML patients with a remarkably good long-term outcome achieved by chemotherapy alone. PMID: 24855032
10. miR-3151 introns within BAALC have roles in driving leukemogenesis by deregulating the TP53 pathway PMID: 24736457
11. Higher BAALC expression and FLT3-ITD mutation, both individually and in combination, were associated with worse survival outcomes in CN-AML, and this was also applicable in NPM1-mutated CN-AML, known as a favorable-risk group. PMID: 23647058
12. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients. PMID: 23760853
13. higher post-HSCT BAALC and WT1 expressions in patients with CBF-AML may be good markers of minimal residual disease for the prediction of survival and relapse after HSCT. PMID: 23672350
14. Investigated the prognostic impact of brain and acute leukemia, cytoplasmic (BAALC) expression in acute myeloid leukemia with normal karyotype. PMID: 23865362
15. data show that higher levels of VEGF-A(CSF) are closely related to CNS leukemia (CNSL), and VEGF-A(CSF) may be a better predictor than the other risk factors elucidating the pathogenesis and development of CNSL PMID: 23287429
16. high expression of miR-3151 is an independent prognosticator for poor outcome in cytogenetically normal-AML and affects different outcome end points than its host gene, BAALC PMID: 22529287
17. A high MEBE (MN1,ERG, BAALC, EVI1) expression score is an unfavorable prognostic marker in Myelodysplastic syndrome and is associated with an increased risk for progression to Acute myeloid leukemia. PMID: 22488406
18. identify a heritable genomic feature predisposing to overexpression of an oncogene (BAALC), thereby possibly leading to enhanced AML leukemogenesis PMID: 22493267
19. These findings indicate that BAALC gene is "paused" and that in leukemia cells its transcription can be activated or repressed by mechanisms acting on epigenetic marks. PMID: 22197554
20. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. PMID: 21967978
21. High BAALC expression levels are associated with acute myeloid leukemia. PMID: 20841507
22. 1-5-6-8 BAALC isoform expression may be associated with an adverse prognosis in pediatric acute myeloid leukemia with normal karyotype. PMID: 20495894
23. In contrast to BAALC, which likely represents only a surrogate marker of treatment failure in acute leukemia, IGFBP7 regulates the proliferation of leukemic cells and might be involved in chemotherapy resistance PMID: 20535151
24. Overexpression of BAALC and ERG either separate or concomitant predict adverse clinical outcome and may define important risk factor in cytogenetically normal acute myeloid leukemia PMID: 19555438
25. High BAALC expression is associated with chemoresistance in adult B-precursor acute lymphoblastic leukemia. PMID: 20065290
26. CEBPA mutation status and BAALC expression are important prognostic factors in acute myeloid leukemia patients with normal cytogenetics. PMID: 20306678
27. BAALC is a relevant prognostic marker in intermediate-risk acute myeloid leukemia patients, with high versus low BAALC expressors showing lower complete remission rate after salvage therapy. PMID: 19943049
28. The BAALC gene, located on chromosome 8q22.3, encodes a protein with no homology to any known proteins or functional domains. PMID: 15604894
29. High transcript levels occur in leukemic blasts from some patients with acute myeloid leukemia. PMID: 15749074
30. Low expression of both ERG and BAALC identifies T-ALL patients with a distinctly favorable long-term outcome. PMID: 17646667
31. high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene-expression profile PMID: 18378853
32. Up-regulation of BAALC gene may be an important alteration in AML-M2 patients with t(8;21) translocation. PMID: 18671757
33. Presence of both EVI1 and/or BAALC in chronic myeloid patients was found to modulate the disease pattern PMID: 18752846

Show More

Hide All

HGNC: 14333

OMIM: 606602

KEGG: hsa:79870

UniGene: Hs.533446